Retatrutide vs Tirzepatide vs Semaglutide: A Research Comparison

These three compounds dominate metabolic-research discussion, and they're constantly compared — but they are not the same molecule, and they don't act on the same receptors. This is a factual comparison for a research audience: what each one is, how they differ at the receptor level, and why, whichever you're studying, the paperwork on the vial matters more than the name on it. It is not medical guidance and not a recommendation for any use in humans.

The one-line difference

The three are best understood as a progression in how many hormone receptors each targets:

• Semaglutide — a single agonist: it targets the GLP-1 receptor alone.
• Tirzepatide — a dual agonist: it targets both the GIP and GLP-1 receptors.
• Retatrutide — a triple agonist: it targets GIP, GLP-1 and the glucagon receptor.

Each step adds a receptor target, and that is the single most important distinction between them in the research literature.

Side-by-side

Molecular weights are nominal figures from public reference sources; always defer to the Certificate of Analysis for the specific lot you're working with.

Why the receptor count matters in research

GLP-1, GIP and glucagon are three distinct signalling pathways. A single-agonist compound like semaglutide isolates one of them; a triple agonist like retatrutide engages all three at once. For a researcher, that means the three compounds are studied as genuinely different tools — the questions you can ask with a triple agonist aren't the same as the ones a single agonist answers. Comparing them isn't about which is "strongest"; it's about which receptor profile fits the model being studied.

Retatrutide (originally designated LY3437943) is the newest of the three and the reason the "triple agonist" term has entered common research vocabulary. Its Phase 2 results were published in the New England Journal of Medicine in 2023, which is what moved it from obscure code-name to widely discussed compound.

The thing all three have in common

Whichever compound a study calls for, the same problem applies: the label doesn't prove the contents. A vial marked "retatrutide" is only retatrutide if a Certificate of Analysis says so — identity confirmed by mass spectrometry, purity measured by HPLC, tied to that specific lot. This is where most of the supply market falls down, and it's the one variable a researcher can actually control before ordering.

At DNR every lot ships with a batch-specific CoA you can check before you buy, not a generic line-level document. That matters more for a triple agonist than almost anything else — a more complex molecule is a more common target for substitution or under-purity, precisely because it's harder for a buyer to verify by eye.

In short

Semaglutide, tirzepatide and retatrutide are a single, dual and triple receptor agonist respectively — one, two and three hormone targets. They're related in the literature but distinct in what they let you study. If your research calls for the triple agonist, the only question that protects you is whether the vial comes with paperwork you can verify.

Browse the DNR research catalogue →

For laboratory and research use only. Not for human consumption. Nothing on this page is medical advice or a claim of any effect in humans; it summarises publicly published research context only.